RadOnc Smart Review

In our last episode, we laid the complete foundation for managing spinal metastases. Today, we transition from the broad strokes of conventional palliation to the high-precision, high-impact world of Stereotactic Body Radiation Therapy, or SBRT. This episode is a practical workshop. We will cover who to treat with SBRT, a deep dive into the conflicting evidence, how to delineate targets with a ste...

In Episode 15a, we covered the comprehensive workup for a patient with suspected spinal metastases, from distinguishing pain types to detailed imaging interpretation and initial supportive care. Today, we move to the definitive decisions. We will master the assessment of spinal stability using the SINS score, delineate the Bilsky scale for grading cord compression, and define the evidence-based ma...

This is Episode 15a, the first in our new two-part foundational series on Spinal Metastases. Today's episode is titled: "Spine Mets Part 1: Anatomy & Initial Workup."Metastatic disease to the spine is one of the most common and challenging scenarios we face. It can cause debilitating pain, catastrophic neurologic injury, and profoundly impact quality of life. Correct management requires a rapi...

This is our mock oral boards for lower GI malignancies. I will present two comprehensive rectal cancer cases, walking you through each one from initial presentation all the way through treatment and follow-up. For each section, I want you to pause and formulate your own structured response before I walk you through the model answer and a key teaching pearl. The goal is to think like an attending a...

Over the last several episodes, we've systematically broken down the evidence that defines modern GI oncology. Today, we put that knowledge to the test. This episode is a mock oral board examination. I will present five comprehensive case blocks, covering Esophageal, Gastric, Pancreatic, Hepatobiliary, and Hepatocellular cancers. For each, I will present a clinical scenario and then pose a series...

This episode is a mock oral boards session. I will present three distinct, challenging clinical scenarios. For each case, we will walk through the entire management process, from initial presentation all the way through treatment and follow-up, to sharpen your clinical decision-making.

Over the past decade, the landscape of systemic therapy has been transformed by the arrival of immunotherapy and highly effective targeted agents. Many of these drugs have significant intracranial activity, creating a new and complex challenge for the radiation oncologist: how do we sequence our treatments? The old paradigm of "radiation first" is no longer always correct. Today, we will provide a...

Today, we address the frontiers of SRS. First, we'll ask: can we treat more than four metastases? Second, how do we safely and effectively treat large metastases that are too big for a single high dose of radiation? And finally, we will tackle the most common and challenging complication of SRS: how to differentiate radiation necrosis from tumor progression.

Today, we will conduct a practical workshop on postoperative stereotactic radiosurgery. We'll dissect the two landmark trials that define this practice, learn how to properly delineate a post-operative target volume, and discuss the dreaded complication of nodular leptomeningeal disease.

In our last episode, we laid the groundwork for managing brain metastases. Today, we tackle one of the most significant paradigm shifts in modern radiation oncology: the move away from routine whole-brain radiotherapy for patients with a limited number of brain metastases. For decades, WBRT was the standard. Now, for many patients, it's an inferior option. We will walk through the chronological st...

Brain metastases are the most common intracranial tumor in adults, and their management has undergone a complete revolution. Before we can treat, we must be able to prognosticate and have a firm grasp of the foundational principles. Today, we will cover the essential background, including epidemiology and workup. We will master the modern prognostic indices, including the Disease-Specific Graded P...

This is Episode 8: Low-Grade Glioma Part 3: Treatment Planning & Case-Based Review. Over the last two episodes, we've built the complete evidence-based framework for managing WHO Grade II gliomas. We've learned how to risk-stratify patients, when to treat, and what regimen to use. Today, we put that knowledge into practice. We'll start with a deep dive into the technical details of treatment p...

This is Episode 7: Low-Grade Glioma Part 2: Evidence for Chemo, Dose, and IDH Inhibitors. In our last episode, we established the framework for managing Grade II gliomas, answering the crucial question of when to treat. Today, we address the next logical question: for those high-risk patients we decide to treat, how do we treat them? We will dissect the pivotal evidence that transformed our approa...

This is Episode 6, and we are kicking off our new mini-series on Low-Grade Gliomas. Today's episode is titled: "LGG P1: Foundations, Risk Stratification & The Timing Debate."For years, the management of WHO Grade II gliomas has been one of the most debated topics in neuro-oncology. These tumors often occur in young, otherwise healthy individuals and have a long natural history, making the deci...

In our first four episodes, we've established the "what" and the "why" of high-grade glioma management. Today, we get practical and move to the "how." Treatment planning is a core competency for any radiation oncologist, and for high-grade gliomas, it's a discipline of millimeters and nuanced judgments.

In our first three episodes, we mastered the standard approach for a "Stupp-eligible" patient with glioblastoma. But as you know, many of our patients do not fit this mold. They are older, have a lower performance status, or present with the formidable challenge of recurrent disease. Today, we address these special cases head-on. We'll build a framework for treating elderly and frail patients, rev...

In our first two episodes, we built the modern diagnostic framework for high-grade gliomas, focusing on anaplastic oligodendrogliomas and astrocytomas. Today, we turn our attention to the most common and most formidable of these tumors: glioblastoma, IDH-wildtype. For years, this diagnosis came with a grim prognosis. But in 2005, one trial created a paradigm shift, establishing the bedrock of mode...

In our last episode, we established the modern molecular framework for diagnosing high-grade gliomas and detailed the management of anaplastic oligodendroglioma. Today, we explore the other side of that coin. We will master the management of anaplastic astrocytoma by dissecting the pivotal CATNON trial, and we’ll tackle a challenging new entity introduced in the 2021 WHO classification: the IDH-mu...

Welcome back to Rad Onc Smart Review, CNS Edition. T his is Episode 1 of our new series on CNS oncology, titled: Modern Classification & Anaplastic Oligodendroglioma Evidence. For decades, we treated high-grade gliomas based on what a pathologist saw under a microscope. But in the last ten years, a molecular revolution has completely rewritten the textbook. You cannot treat what you can't accu...

This is Episode 20B: Anal Cancer Part 4: Guidelines, Toxicity, Follow-Up & Future Directions. Over the last three episodes, we've built a comprehensive understanding of anal cancer, from its foundational anatomy and staging, to the landmark trials that established definitive chemoradiation, and the technical details of modern IMRT planning. We've learned the 'what,' 'why,' and 'how' of our sta...

In our last episode, we established the foundations of anal cancer therapy, proving that definitive chemoradiation with 5-FU and Mitomycin-C is the organ-preserving standard of care. But while this approach is highly effective, it is also notoriously toxic. The older 3D radiation techniques often led to severe side effects and treatment breaks that compromised outcomes. Today, we focus on the mode...

In our last episode, we laid the foundation for anal cancer management, establishing definitive concurrent chemoradiation as the sphincter-sparing standard of care, thanks to the pioneering work of Dr. Nigro and the pivotal ACT I and EORTC trials. We know why we use chemoradiation. Today, we focus on how to optimize it. Modern chemoradiation for anal cancer is a finely tuned balance of three criti...

We've arrived at our final primary site in the lower GI tract: anal cancer. In many ways, this disease is the ultimate success story for radiation oncology. It is one of the few solid tumors where we have moved from a paradigm of radical, mutilating surgery to a non-operative, organ-preserving standard of care, with definitive chemoradiation as the backbone. Today, we'll trace the history of this...

Today, in our final episode on rectal cancer, we'll equip you with practical strategies for managing acute on-treatment toxicities. We'll then delineate evidence-based follow-up schedules, contrasting operative and non-operative approaches. Finally, we'll explore key survivorship considerations, including fertility preservation, bone health, and the crucial role of pelvic floor rehabilitation.

Today, we're stepping into the treatment planning suite. We'll walk through the entire process, from patient education and simulation setup to the meticulous art of target volume delineation and the critical science of dose selection and OAR constraint application. This episode is your hands-on guide to building a high-quality rectal cancer radiation plan.